Novus Scientific, an innovator in the development and commercialization of resorbable synthetic medical devices, has announced that the Intellectual Property portfolio of TIGR Matrix Surgical Mesh has been further complimented with the granting of a second US patent related to material degradation and mechanical behaviour.

TIGR Matrix was developed based on the hypothesis that soft tissue positively remodels in response to the stimulus of increased mechanical load – a process known as 'mechanotransduction', which is the physiological process by which cells sense and respond to mechanical loads. This key feature contributes to the functional regenerated tissue that ultimately replaces the degraded mesh, as shown in preclinical trials.

TIGR Matrix Surgical Mesh is the World's 1st Long-Term Resorbable, (100% Absorbable) Synthetic Mesh indicated for reinforcement of soft tissue where weakness exists. Its unique patented dual-fiber construction is designed for gradually increasing mechanical compliance, making it strong for 6 months and gone in 3 years. The US Food and Drug Administration (FDA) gave the company 510(k) clearance to market TIGR Matrix Surgical Mesh in February 2010. In August 2011 Novus Scientific received CE Mark approval from BSI for TIGR Matrix Surgical Mesh in Europe.

The first US patent covered the interlocking structure of a knitted mesh implant. The mechanotransductional function of TIGR Matrix is now further protected.

Roger Johansson, vice president Sweden said: “This is a step toward protecting the basic underlying technology behind TIGR Matrix Surgical Mesh. To have it safely on file alongside our other US and European patents increases our stake in the niche market of which we are sole initiator thus far, and represents real value to Novus Scientific and the future of TIGR Matrix.”

TIGR Matrix Surgical Mesh is available for sale in the US and selected countries in Europe and Asia.